Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate

Hoth Therapeutics (HOTH) announced “promising” findings for its novel therapeutic candidate, HT-001, a topical neurokinin 1 receptor antagonist, in the treatment of Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions. The data will be presented at the American Academy of Dermatology 2025 Annual Meeting, which takes place March 7-11, 2025, highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities. A recent case study demonstrated the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab. The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors. After just one week of applying HT-001 2% cream twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks. “These findings demonstrate the potential of HT-001 as a safe and effective therapy for EGFR inhibitor-associated skin toxicities,” said Robb Knie, CEO at Hoth Therapeutics. “With a significant unmet need for long-term, well-tolerated treatment options, HT-001 could offer relief to cancer patients experiencing debilitating skin reactions.”